SNORD114-29: A Potential Drug Target and Biomarker for Small Nucleolar RNA

Target Name: SNORD114-29

NCBI ID: G767610

SNORD114-29

Other Name(s): Small nucleolar RNA, C/D box 114-29 | small nucleolar RNA, C/D box 114-29 | 14q(II-29)

SNORD114-29: A Potential Drug Target and Biomarker for Small Nucleolar RNA

Small nucleolar RNA (snRNA) is a non-coding RNA molecule that plays a critical role in the regulation of gene expression in eukaryotic cells. One of the well-known classes of snRNA is C/D box snRNA (CISN), which are composed of a conserved core region and a unique C/D region. C/D box snRNA are involved in various cellular processes, including DNA replication, transcription, and RNA processing. The discovery of new C/D box snRNA has the potential to shed light on the mechanisms of gene regulation and may lead to the development of new therapeutic strategies.

SNORD114-29 is a C/D box snRNA that has been identified as a potential drug target and biomarker. Its unique structure and function make it an attractive target for research into small nucleolar RNA-mediated gene regulation.

Structure and Function

SNORD114-29 has a length of approximately 29 nucleotides and consists of a single exon. The 5' end of the exon is a GCAATTTG base, while the 3' end is a GCTCGTA base. The C/D region of SNORD114-29 is composed of 114 nucleotides and has a specific structure that includes a 5' splice site, a 2' leader region, a 3' variable exon, and a 5' extension.

The 5' splice site is a critical region of the C/D region that is involved in the splicing of RNA. The 2' leader region is a conserved region that is located upstream of the 5' splice site and functions as a binding site for splicing factors. The 3' variable exon is the variable region of the snRNA that is responsible for encoding specific amino acids. Finally, the 5' extension is the tail region of the snRNA that includes a poly(A) tail and a 2' non -coding region that has not been fully characterized.

Function

SNORD114-29 is involved in various cellular processes, including DNA replication, transcription, and RNA processing. One of the well-known functions of SNORD114-29 is its role in the regulation of gene expression. Specifically, it has been shown to play a role in the regulation of microRNA (miRNA) expression. miRNA are small non-coding RNAs that play a critical role in post-transcriptional gene regulation by binding to specific target genes and affecting their stability.

Studies have shown that SNORD114-29 can interact with miRNA-21, a well-known regulator of gene expression. This interaction occurs in the 5' splice site of SNORD114-29 and results in the formation of a complex between SNORD114-29 and miRNA -21. This complex can then recruit miRNA-21 to target specific genes for degradation.

Drug Target

The unique structure and function of SNORD114-29 make it an attractive target for drug research. The discovery of SNORD114-29 has also led to the identification of new potential drug targets for the treatment of various diseases, including cancer.

One of the potential drug targets for SNORD114-29 is the inhibition of its activity. This can be achieved by targeting the C/D region of SNORD114-29, which is known to be involved in the regulation of miRNA expression. The development of small molecules that specifically target the C/D region of SNORD114-29 may provide a new therapeutic strategy for the treatment of various diseases.

Biomarker

SNORD114-29 can also be used as a biomarker for the diagnosis and monitoring of certain diseases. For example, the expression of SNORD114-29 has been shown to be affected by various environmental factors, including radiation and chemistry

Protein Name: Small Nucleolar RNA, C/D Box 114-29

The "SNORD114-29 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORD114-29 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets